NCT01044329 (BRVO) is a Phase 2 clinical trial of Bevacizumab in Branch Retinal Vein Occlusion, sponsored by Shahid Beheshti University of Medical Sciences.

Who is sponsoring NCT01044329?

NCT01044329 is sponsored by Shahid Beheshti University of Medical Sciences.

What drugs are being tested in NCT01044329?

Interventions in NCT01044329: Bevacizumab, Triamcinolone Acetonide.

What condition does NCT01044329 study?

NCT01044329 studies Branch Retinal Vein Occlusion.

Is NCT01044329 still recruiting?

NCT01044329 is currently status unknown. Last updated 6 January 2010.

Last reviewed 2010-01-06 · How we verify

NCT01044329: BRVO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion

Status unknown Phase 2 Last updated 6 January 2010

What this trial tests

Phase 2 trial testing Bevacizumab in Branch Retinal Vein Occlusion in 90 participants. Status unknown.

Timeline

1 January 2010

Primary endpoint
1 August 2010

1 December 2010

Quick facts

Lead sponsor	Shahid Beheshti University of Medical Sciences
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	90
Start date	1 January 2010
Primary completion	1 August 2010
Estimated completion	1 December 2010
Sites	1 location across Iran

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Triamcinolone Acetonide — full drug profile →

Conditions studied

Branch Retinal Vein Occlusion — all drugs for Branch Retinal Vein Occlusion →

Sponsor

Shahid Beheshti University of Medical Sciences

Who can join

Eligibility, any sex, with Branch Retinal Vein Occlusion. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Visual acuity
Time frame: 6 months

Sponsor's own description

This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Anti-vascular endothelial growth factor for macular oedema secondary to branch retinal vein occlusion.
Shalchi Z, Mahroo O, Bunce C, Mitry D. · · 2020 · cited 26× · PMID 32633861 · DOI 10.1002/14651858.cd009510.pub3
The efficacy and safety of intraocular anti-VEGF injections versus anti-VEGF combined with steroids or steroid monotherapy for macular edema secondary to retinal vein occlusion: a systematic review and meta-analysis of randomized controlled trials.
Cai H, Tian M, Huang Z, Wang B. · · 2025 · PMID 41601793 · DOI 10.3389/fmed.2025.1727801

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Branch Retinal Vein Occlusion

Currently open trials in the same condition.

NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting

Other Shahid Beheshti University of Medical Sciences trials

Trials by the same sponsor.

NCT07005687 — Using MSCs for Chronic Active Antibody Mediated Rejection · NA · not yet recruiting
NCT07435558 — Homogeneous vs. Heterogeneous Learning Style Grouping in Problem-Based Learning Among Nurses · NA · not yet recruiting
NCT07408492 — Impact of AI-Based Research Training on Nursing Students · NA · not yet recruiting
NCT07176663 — Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure · NA · not yet recruiting
NCT07291622 — Synchrony-Optimized Non-Invasive Ventilation Education Program and ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01044329 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shahid Beheshti University of Medical Sciences
Last refreshed: 6 January 2010

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01044329.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing